vs

Side-by-side financial comparison of American Express (AXP) and Kymera Therapeutics, Inc. (KYMR). Click either name above to swap in a different company.

American Express is the larger business by last-quarter revenue ($18.9M vs $11.5M, roughly 1.6× Kymera Therapeutics, Inc.). American Express runs the higher net margin — 15.7% vs -667.6%, a 683.3% gap on every dollar of revenue. On growth, American Express posted the faster year-over-year revenue change (11.4% vs -55.3%). Over the past eight quarters, Kymera Therapeutics, Inc.'s revenue compounded faster (10.1% CAGR vs -95.6%).

American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...

Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.

AXP vs KYMR — Head-to-Head

Bigger by revenue
AXP
AXP
1.6× larger
AXP
$18.9M
$11.5M
KYMR
Growing faster (revenue YoY)
AXP
AXP
+66.7% gap
AXP
11.4%
-55.3%
KYMR
Higher net margin
AXP
AXP
683.3% more per $
AXP
15.7%
-667.6%
KYMR
Faster 2-yr revenue CAGR
KYMR
KYMR
Annualised
KYMR
10.1%
-95.6%
AXP

Income Statement — Q1 FY2026 vs Q2 FY2025

Metric
AXP
AXP
KYMR
KYMR
Revenue
$18.9M
$11.5M
Net Profit
$3.0M
$-76.6M
Gross Margin
Operating Margin
-736.8%
Net Margin
15.7%
-667.6%
Revenue YoY
11.4%
-55.3%
Net Profit YoY
15.0%
-82.1%
EPS (diluted)
$-0.95

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXP
AXP
KYMR
KYMR
Q1 26
$18.9M
Q4 25
$10.9B
Q3 25
$10.4B
Q2 25
$10.3B
$11.5M
Q1 25
$9.6B
$22.1M
Q4 24
$10.0B
$7.4M
Q3 24
$9.7B
Q2 24
$9.8B
$25.6M
Net Profit
AXP
AXP
KYMR
KYMR
Q1 26
$3.0M
Q4 25
$2.5B
Q3 25
$2.9B
Q2 25
$2.9B
$-76.6M
Q1 25
$2.6B
$-65.6M
Q4 24
$2.2B
$-70.8M
Q3 24
$2.5B
Q2 24
$3.0B
$-42.1M
Operating Margin
AXP
AXP
KYMR
KYMR
Q1 26
Q4 25
28.2%
Q3 25
36.7%
Q2 25
34.4%
-736.8%
Q1 25
34.6%
-336.8%
Q4 24
27.7%
-1092.2%
Q3 24
33.0%
Q2 24
38.6%
-198.5%
Net Margin
AXP
AXP
KYMR
KYMR
Q1 26
15.7%
Q4 25
22.5%
Q3 25
27.9%
Q2 25
28.0%
-667.6%
Q1 25
26.8%
-296.7%
Q4 24
21.8%
-956.9%
Q3 24
25.8%
Q2 24
30.7%
-164.0%
EPS (diluted)
AXP
AXP
KYMR
KYMR
Q1 26
Q4 25
$3.52
Q3 25
$4.14
Q2 25
$4.08
$-0.95
Q1 25
$3.64
$-0.82
Q4 24
$3.04
$-0.89
Q3 24
$3.49
Q2 24
$4.15
$-0.58

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXP
AXP
KYMR
KYMR
Cash + ST InvestmentsLiquidity on hand
$335.8M
Total DebtLower is stronger
$60.4M
Stockholders' EquityBook value
$34.0M
$971.5M
Total Assets
$308.9M
$1.1B
Debt / EquityLower = less leverage
1.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXP
AXP
KYMR
KYMR
Q1 26
Q4 25
$742.0M
Q3 25
$1.3B
Q2 25
$197.0M
$335.8M
Q1 25
$261.0M
$90.0M
Q4 24
$221.0M
$120.3M
Q3 24
$120.0M
Q2 24
$188.0M
$67.6M
Total Debt
AXP
AXP
KYMR
KYMR
Q1 26
$60.4M
Q4 25
$56.4B
Q3 25
$57.8B
Q2 25
$58.2B
Q1 25
$51.2B
Q4 24
$49.7B
Q3 24
$53.5B
Q2 24
$51.5B
Stockholders' Equity
AXP
AXP
KYMR
KYMR
Q1 26
$34.0M
Q4 25
$33.5B
Q3 25
$32.4B
Q2 25
$32.3B
$971.5M
Q1 25
$31.2B
$786.2M
Q4 24
$30.3B
$835.6M
Q3 24
$29.7B
Q2 24
$29.5B
$684.9M
Total Assets
AXP
AXP
KYMR
KYMR
Q1 26
$308.9M
Q4 25
$300.1B
Q3 25
$297.6B
Q2 25
$295.6B
$1.1B
Q1 25
$282.2B
$918.3M
Q4 24
$271.5B
$978.0M
Q3 24
$271.0B
Q2 24
$272.2B
$826.0M
Debt / Equity
AXP
AXP
KYMR
KYMR
Q1 26
1.78×
Q4 25
1.68×
Q3 25
1.78×
Q2 25
1.80×
Q1 25
1.64×
Q4 24
1.64×
Q3 24
1.80×
Q2 24
1.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXP
AXP
KYMR
KYMR
Operating Cash FlowLast quarter
$-59.9M
Free Cash FlowOCF − Capex
$-60.6M
FCF MarginFCF / Revenue
-527.9%
Capex IntensityCapex / Revenue
6.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-250.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXP
AXP
KYMR
KYMR
Q1 26
Q4 25
$3.1B
Q3 25
$6.2B
Q2 25
$4.4B
$-59.9M
Q1 25
$4.8B
$-79.2M
Q4 24
$5.8B
$-61.8M
Q3 24
$-1.8B
Q2 24
$4.5B
$-42.9M
Free Cash Flow
AXP
AXP
KYMR
KYMR
Q1 26
Q4 25
$2.3B
Q3 25
$5.6B
Q2 25
$3.7B
$-60.6M
Q1 25
$4.3B
$-79.6M
Q4 24
$5.3B
$-62.7M
Q3 24
$-2.3B
Q2 24
$4.0B
$-47.6M
FCF Margin
AXP
AXP
KYMR
KYMR
Q1 26
Q4 25
21.4%
Q3 25
53.6%
Q2 25
36.3%
-527.9%
Q1 25
45.0%
-360.3%
Q4 24
53.1%
-848.3%
Q3 24
-23.3%
Q2 24
40.4%
-185.7%
Capex Intensity
AXP
AXP
KYMR
KYMR
Q1 26
Q4 25
6.6%
Q3 25
6.3%
Q2 25
6.0%
6.1%
Q1 25
4.5%
2.1%
Q4 24
5.0%
12.7%
Q3 24
4.7%
Q2 24
5.8%
18.3%
Cash Conversion
AXP
AXP
KYMR
KYMR
Q1 26
Q4 25
1.25×
Q3 25
2.15×
Q2 25
1.51×
Q1 25
1.84×
Q4 24
2.66×
Q3 24
-0.72×
Q2 24
1.50×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXP
AXP

Discount revenue$9.5M50%
Other$8.9M47%
Deposits with banks and other$512.0K3%

KYMR
KYMR

Segment breakdown not available.

Related Comparisons